Pfizer announces appointment of Chief Business Innovation Officer

Malik succeeds John Young, who recently announced his intent to retire after a 34-year career at Pfizer. Mr. Malik begins his role on August 30, 2021 and will work with John to ensure a seamless transition

Pfizer has announced Aamir Malik has joined the company as Executive VP and Chief Business Innovation Officer. Malik will be a member of the company’s executive leadership team reporting to Chair and CEO, Albert Bourla. Malik joins Pfizer from McKinsey & Company, where he most recently served as the Managing Partner responsible for the firm’s US operations. Previously, he led its Global Pharmaceuticals & Medical Products practice.

At Pfizer, Malik will oversee the company’s strategy, business development, portfolio management, pipeline prioritisation, and formation of business ventures, as well as the advancement of access partnerships with payers and governments around the world.

“We are delighted to welcome Aamir Malik to our executive leadership team in this important role as we enter the next era of innovation for Pfizer and continue our pursuit of both cutting-edge science and opportunities to reimagine how we do business for the benefit of patients and society,” said

Albert Bourla, Chairman and CEO, Pfizer. “Aamir brings with him 25 years of experience developing innovative growth strategies, guiding mergers and acquisitions, and implementing high-impact programs to improve patients' lives and transform performance for life science companies. He is the ideal leader to drive these efforts.”

Malik earned a Bachelor of Science in finance from Indiana University and currently serves on the University’s Kelley School of Business Dean’s Council.

You may also like